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Sfactor for MACE (OR¼2.4; p¼0.04), and death (OR¼6.8; p¼0.001). Upon multi-
variate logistic regression adjusting for CKD, DEB/DES length, and focal ISR, DEB
was not associated with MACE (OR¼0.9; p¼0.71) or death (OR¼1.7; p¼0.44).
Conclusions: Chronic kidney disease is an independent predictor of adverse outcomes
following percutaneous treatment of ISR. When adjusted for confounders, DEB and
DES are associated with similar outcomes in this setting.
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Impact of Stent Recoil and Fracture in RCA Ostium Restenosis Following
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Background: PCI procedure of RCA ostium stenosis is still a challenging issue due to
high stent restenosis rate, possibly due to mechanical stress. However, mechanisms of
restenosis following cobalt-chromium everolimus-eluting stent (EES) or stainless steel
biolimus-eluting stent (BES) implantation have not been well clariﬁed.
Methods: Sixty-fourRCAostium restenosis cases after 2ndgenerationDES (40EESand
24 BES) were retrospectively analyzed. Serial (post initial stent and follow-up as revas-
cularization) angiographic and IVUS evaluation were performed. In quantitative angio-
graphic analysis (QCA), incidence of stent fracture (deﬁned as complete separation of the
stent segments and/or the absence of a stent strut on magniﬁed ﬂuoroscopic image), and
partial (only one of the inner or outer struts was separated) and complete (both the inner
and outer struts were disconnected) fracture type were evaluated. In IVUS, serial changes
ofminimum lumen and stent area (SA), and degree of stent recoil atminimum lumen area,
deﬁned as (follow-up SA - baseline SA / baseline SA*100), were also measured.
Results: Average follow-up phase was 1410-months. Angiographic and IVUS
morphometric parameters were similar in both groups at baseline. Signiﬁcant lumen
narrowingwas observed from baseline to follow-up in both groups (10.24.6 to 2.52.0,
10.75.4 to 2.42.3 mm2 in minimum lumen area, EES vs. BES, p<0.01 from baseline
to follow-up for all). Stent fracturewasmore frequently observed inBES than EES (85 vs.
8%, p<0.01). In addition, complete fracturewas highly observed inBES (29%) compared
to EES (2%, p<0.05). In contrast, signiﬁcant stent recoil was observed in EES only
(11.85.7 to 9.05.4 mm2, p<0.01 from baseline to follow-up for EES, 11.64.8 to
11.33.4 mm2, p¼ns for BES, and degree of stent recoil was signiﬁcantly larger in EES
than BES (23.8 vs. 2.6%, p<0.05). Additionally, there was only 1 BES and no EES case
that both stent fracture and signiﬁcant recoil, resulting in stent restenosis, was observed.
Conclusions: Stent fracture appears to be the major cause of RCA ostium restenosis
after stainless steel BES, whereas stent recoil seem to be associated with restenosis
after cobalt-chromium EES.
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Background: Stent fracture (SF) is one of the complications after percutaneous
coronary intervention (PCI), although it is not often. To date many data on ﬁrst
generation drug-eluting stent (DES) fracture were published. However study on
second generation DES fracture is rare. The aim of this study was to assess the
predictors of second generation DES fracture.
Methods: From March 2010 to August 2012, a total of 1032 patients with 1283 lesions
who underwent successful implantation with second generation DES at Inje University
HaeundaePaikHospitalwere followed prospectively.Among them, 369 patients (35.7%)
with 476 (37.1%) lesions who underwent follow-up coronary angiography (CAG) 6 to 12
months after initial procedure, irrespective of clinical symptoms, were performed.
Results: SF was identiﬁed in 45 of 1032 patients (4.36%) and 51 of 1283 lesions
(3.82%). The patients were divided into SF group and non-SF group. The most
prevalent vessel of SF was the left anterior descending artery (24 lesions, 47.1%),
followed by the right coronary artery (16 lesions, 31.4%). Most lesions were classiﬁed
as type B2 (15 lesions, 29.4%) or type C (22 lesions, 43.2%). All implanted stents
were the second generation DES such as everolimus-eluting stents (17 stents, 33.3%),
zotarolimus-eluting stents (12 stents, 23.5%) and biolimus-eluting stents (10 stents,
19.7%). Compared with non-SF group, SF group was more likely to have stent
overlap (52.4% vs. 22.4%; p<0.001) and peri-procedural myocardial infarction
(32.6% vs. 12.1%; p<0.001). On multivariate logistic regression analysis, stent
overlap (odds ratio 3.45, 95% conﬁdence interval 1.66-7.17, p<0.001), Biolimus-
eluting stents (odds ratio 6.17, 95% conﬁdence interval 2.19, p<0.001), stent length
(odds ratio 1.07, 95% conﬁdence interval 1.02-1.13, p¼0.009), and peri-procedural
MI (odds ratio 3.14, 95% conﬁdence interval 1.36-7.23, p ¼0.007), were identiﬁed as
independent predictors for fracture of second generation stent.
Conclusions: The incidence of stent fracture in the second generation DES was
3.82%. The biolimus-eluting stent, overlapping stent, peri-procedural MI, and long
stent length are signiﬁcant determinants of stent fracture in the second generation.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-453
Multiple Predictors of In-Stent Restenosis with Clinical Presentation of Acute
Coronary Syndrome After Drug-Eluting Stent Implantation
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Background: Although in-stent restenosis (ISR) after drug-eluting stent (DES) is
perceived to be a benign phenomenon, some patients with ISR showed clinical presen-
tation of acute coronary syndrome (ACS). We sought to identify parameters inﬂuencing
the likelihood of restenosis with clinical presentation of ACS after DES implantation.
Methods: Stented patients (n¼3,817) with DESs were retrospectively reviewed for
inclusion in the study from theKoreaUniversity PCIDatabase Registry. From this database,
age and sex-matched 302 patients (7.9%) with ISR were assigned to either the Stable ISR
group (n¼156) or the ACS ISR group (n¼146). Predictors of coronary restenosis with
clinical presentation of ACS were identiﬁed with Cox regression analyses.
Results: The rate of risk factors such smoking, hypertension, and diabetes were similar
between the 2 groups; moreover, the use of medications at baseline did not differ
signiﬁcantly between the 2 groups. More patients in the ACS ISR group showed two
vessel diseases (n¼70 [47.9%] vs. n¼44 [28.2%], P¼0.028, respectively). No signiﬁ-
cant differences in ISR pattern were noted between the 2 groups during the follow-up
angiogram. Follow-up MMP-2 level was signiﬁcantly higher in the ACS ISR group
when compared to the Stable ISRgroup (66,639+/-12,519 vs. 57,386+/-2,423, P¼0.011,
respectively). Age (Hazard ratio [HR], 1.13; 95% conﬁdence interval [CI], 1.02 to 1.26;
P¼0.024), diabetes (HR, 6.80; 95% CI, 1.16 to 39.9; P¼0.034), the use of aspirin (HR,
0.005; 95% CI, 0.001 to 0.760; P¼0.039), clopidogrel (HR, 0.010; 95% CI, 0.001 to
0.162; P¼0.001), ACE inhibitor (HR, 0.210; 95%CI, 0.003 to 0.515; P<0.001), the use
ofﬁrst generationDES (HR, 1.130; 95%CI, 1.030 to 1.260; P¼0.001), andMMP-2 level
(HR, 1.120; 95% CI, 1.001 to 1.190; P¼0.004) during follow-up were signiﬁcant
predictors of ISR with clinical presentation of ACS during the 3-year follow-up.
Conclusions: In the era of DES, older age, diabetes, the use of ﬁrst generation DES,
and increased MMP-2 levels were signiﬁcant predictors of ISR with clinical presen-
tation of ACS. In contrast, the use of aspirin, clopidogrel, high-dose statin, and ACE
inhibitor prevented ISR with clinical presentation of ACS.
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Background: Stent fracture (SF) after drug-eluting stent implantation has recently
became an important concern. However, the incidence and clinical impact of SF after
the Nobori biolimus-eluting stent (BES) remains unclear.
Methods: A total of 1031 patients with 1407 lesions undergoing BES implantation
and follow-up angiography 6 to 9 months after index procedure were analyzed. SF
was deﬁned as complete or partial separation of the stent, as assessed by plain ﬂuo-
roscopy, intravascular ultrasound, or optical coherence tomography during follow-up.
We assessed the rate of SF and major adverse cardiac events (MACE), deﬁned as
cardiac death, myocardial infarction, stent thrombosis, and clinically driven target
lesion revascularization (TLR) within 9 months.
Results: SF was observed in 58 of 1407 lesions (4.1%) and 57 of 1031 patients (5.5%).
Lesions with hinge motion (odd ratio [OR], 6.15; 95% conﬁdence interval [CI], 3.40-
11.46; p<0.001), tortuosity (OR, 3.12; 95% CI, 1.46-7.31; p¼0.003), or overlapping
stents (OR, 2.66; 95% CI, 1.23-5.81; p¼0.013) were independent predictors of SF. The
MACE rate within 9months were signiﬁcantly higher in the SF group than in the non-SF
group (28.1% vs. 4.6%, p<0.001). The rate of TLR was signiﬁcantly higher in the SF
group than in the non-SF group (28.0% vs. 4.1%, p<0.001), whereas the rate of
myocardial infarction and stent thrombosis were not different between the 2 groups
(1.8% vs. 1.0%, p¼0.61; 1.8% vs. 0.9%, p¼0.53, respectively).acts/POSTER/In-stent Restenosis and Stent Thrombosis B139
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rate of MACE, driven by higher rate of TLR.
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Background: Though percutaneous coronary intervention with the XIENCE V ever-
olimus-eluting stent (EES, Abbott Vascular, Santa Clara, CA) for native coronary artery
disease has favorable results compared to ﬁrst generation drug-eluting stents, outcomes
with EES for the treatment of in-stent restenosis (ISR) are unknown. The objective of this
study is to evaluate the safety and efﬁcacy of XIENCE V for the treatment of ISR.
Methods: XIENCE V USA is a prospective observational multicenter registry eval-
uating clinical outcomes in patients who received treatment with EES. In this study,
we present the 1-year clinical outcomes in patients who received EES for the treatment
of ISR and non-ISR in this registry. The primary outcome was the composite of target
lesion failure (deﬁned as cardiac death, target vessel myocardial infarction, or target
lesion revascularization). Secondary outcomes were myocardial infarction, target
lesion revascularization, and stent thrombosis.
Results: In this registry 383 patients (6411 years old; 68.4% male) received
revascularization for single-vessel ISR and 4832 patients (6411 years old; 69.0%
male) received revascularization for non-ISR lesions. At 1 year, the rate of clinical
adverse events (Table) was higher in the ISR group compared the non-ISR group,
however, these differences ceased to exist when case-control matched patients in the
non-ISR group were studied.
Conclusions: The treatment of ISR with EES appears to be safe and efﬁcacious at
1-year follow-up. Compared to the non-ISR group, the rate of target lesion failure was
much higher indicating a higher risk proﬁle of these patients. However, these
differences ceased to exist with case controlled matching.Table. Clinical outcomes at 1 year.
ISR Group (N=383)
Non-ISR Group
(N=4,832)
Case-Matched Non-
ISR Group (N=317)
Target Lesion Failure
(ARC MI)
12.5% 7.0% 10.5%
Myocardial Infarction
(ARC)
7.2% 5.8% 7.1%
Target Lesion
Revascularization
10.3% 2.9% 6.8%
Stent thrombosis
(ARC Deﬁnite)
1.7% 0.2% 0.7%TCT-456
The Impact of Atherogenic Neointima on Long-term Clinical Outcomes: An
Observational Study from the Optical Coherence Tomography Registry
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1Kobe University Graduate School of Medicine, Department of Cardiology, Kobe,
Japan
Background: Pathological studies have revealed atherosclerotic neointima (AN) after
stent implantation. However, the risk factor of neoatherosclerosis and its impact on
future clinical events remain unclear.
Methods: From the Kobe university OCT database, 137 consecutive patients (253
stents) who underwent OCT examination at >1 year after bare metal or ﬁrst-gener-
ation drug-eluting stent implantation were enrolled. We assessed AN (neointima
containing a diffuse border, signal-poor region with invisible struts underneath) by
follow-up OCT and compared major adverse cardiovascular event (MACE: death,
recurrent myocardial infarction and target lesion revascularization (TLR)) rate
between +AN and –AN group.
Results: 38 patients had AN at follow-up OCT, who had higher LDL-cholesterol and
high sensitivity CRP (hs-CRP) level. In multivariate logistic analysis, LDL cholesterol
and hs-CRP were the independent predictors of the presence of AN (OR 1.025
(P¼0.011), OR 1.016 (P¼0.045), respectively). The rate of MACE were signiﬁcantly
higher in +AN than in -AN for an average follow-up of 58 months after stenting. AfterB140 JACC Vol 62/18/Suppl B j October 27–November 1, 20multivariate cox hazard analysis, the presence of AN remained an independent risk
factor of MACE (HR 2.345, 95% CI 1.010-5.440, P¼0.047).Conclusions: Increased LDL-cholesterol and hs-CRP level may be risk factors for AN
progression in patients treated with coronary stents. In this study, the presence of AN
assessed by OCT were independently associated with MACE at >1 year after stent
placement, suggesting a need for careful clinical follow-up of patients with AN.
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Background: The clinical presentation of bare metal in-stent restenosis (ISR) is re-
ported to be associated with high rates of morbidity, including myocardial infarction
(MI). This study aimed to compare the clinical presentation and outcomes between
patients treated with 1st- versus 2nd-generation drug-eluting stents (DES) and pre-
sented with ISR on admission.
Methods: The study identiﬁed ﬁrst episode 1st or 2nd-generation DES ISR patients
who underwent re-intervention. The clinical presentation at admission was classiﬁed
as non acute (asymptomatic or stable angina) or acute (unstable angina, Canadian
Cardiovascular Society (CCS) III or IV and MI). We compared the 1st- vs. 2nd-gen
DES ISR clinical presentation and the rates of major adverse cardiac events (MACE)
as a composite of death, Q-wave MI and target lesion revascularization at 6 months.
Results: Overall, 709 patients with 1095 DES ISR lesions (1st-gen DES n¼526; 2nd-
gen DES n¼113) were selected. The mean age was 65  10 years and diabetics
comprised 49%. Clinical presentation included asymptomatic/stable angina in 29%,
unstable angina in 62% and MI in 8%. Patients with 2nd-generation DES ISR were
less likely to present as MI(13% vs. 5%; p¼0.05) and with severe symptoms (73% vs.
49%, p<0.01) as compared to 1st-gen DES. The incidence of MACE in the 1st- and
2nd-gen DES at 6 months was 8% and 9%, respectively (p¼1.0).
Conclusions: 2nd-generation DES ISR clinical presentation appears to be more
benign with less frequency of MI and CCS III or IV symptoms compared to 1st-
generation DES. The rates of MACE were similar at 6 months.TCT-458
Angiographic localized haziness after drug-coated balloon angioplasty in de-novo
lesions does not increase the risk of acute coronary thrombosis
Theresa Weichert1, Annette Fengler1, Philip Steen1, Klaus Bonaventura1
1Klinikum Ernst von Bergmann, Potsdam, Germany
Background: Clinical studies demonstrated the effectiveness and safety of drug-coated
balloon (DCB) in various clinical scenarios and support the use of paclitaxel-coated
balloon for the treatment of in-stent restenosis, of small coronary arteries and bifurcation
lesions.A fewsmall scale studies have reported excellent immediate and short term results
of DCB use compared to non-coated balloon for de-novo lesions. Initial angiographic13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
